Luttge W G, Rupp M E, Davda M M
Department of Neuroscience, University of Florida College of Medicine, Gainesville 32610.
Endocrinology. 1989 Aug;125(2):817-24. doi: 10.1210/endo-125-2-817.
The concentrations of type I and type II adrenocorticosteroid receptors in brain cytosol obtained from adrenalectomized-ovariectomized female mice were measured with five different assay conditions. Among the five brain regions studied, hippocampus had the highest concentration of type I receptors, whereas cerebral cortex had the highest concentration of type II receptors. The value of properly correcting for dexamethasone cross-binding to type I receptors when type II receptors are being assayed was demonstrated using the type II receptor-selective ligand RU28362. A time-course study revealed a transient up-regulation of both receptor classes in most brain regions after adrenalectomy-ovariectomy, with maximal values achieved 3-5 days postsurgery and a reduction to near-intact levels by 16 days postsurgery. A single sc injection of aldosterone given to adrenalectomized-ovariectomized mice produced a profound down-regulation of type I receptors in hippocampal, cerebral cortex, hypothalamic, brain stem, and cerebellar samples, whereas it down-regulated type II receptors only in hippocampal and cerebral cortical samples. A similar injection of RU28362 failed to down-regulate type I receptors in any brain region, but it did reduce the concentration of type II receptors in all brain regions except cerebellum. The actions of aldosterone appear to be mediated solely through type I receptors, since injections of the type I receptor antagonist RU26752 prevented aldosterone-induced down-regulation of both type I and type II receptors, whereas RU26752 had no effect on the down-regulatory actions of RU28362. The ability of aldosterone to down-regulate type I, but not type II, receptors in hypothalamic, brain stem, and cerebellar samples suggests that type I and type II receptors are concentrated in separate populations of cells in these brain regions, whereas in hippocampus and cerebral cortex there is a sufficient degree of colocalization to permit type II receptor down-regulation via the action of aldosterone-type I receptor complexes. We speculate that this action is mediated at least in part at the genomic level by the suppression of type I and type II receptor mRNA synthesis brought about by the interactions of transformed aldosterone-type I receptor complexes with the DNA regulatory elements upstream from the genes for these receptors.
在五种不同的测定条件下,对取自肾上腺切除 - 卵巢切除雌性小鼠的脑细胞质中I型和II型肾上腺皮质类固醇受体的浓度进行了测量。在所研究的五个脑区中,海马体的I型受体浓度最高,而大脑皮层的II型受体浓度最高。使用II型受体选择性配体RU28362证明了在测定II型受体时正确校正地塞米松与I型受体交叉结合的重要性。一项时间进程研究显示,在肾上腺切除 - 卵巢切除术后,大多数脑区的这两类受体都有短暂的上调,术后3 - 5天达到最大值,术后16天降至接近完整水平。对肾上腺切除 - 卵巢切除的小鼠单次皮下注射醛固酮,可使海马体、大脑皮层、下丘脑、脑干和小脑样本中的I型受体显著下调,而仅在海马体和大脑皮层样本中使II型受体下调。类似地注射RU28362未能使任何脑区的I型受体下调,但确实降低了除小脑外所有脑区的II型受体浓度。醛固酮的作用似乎仅通过I型受体介导,因为注射I型受体拮抗剂RU26752可阻止醛固酮诱导的I型和II型受体下调,而RU26752对RU28362的下调作用没有影响。醛固酮能够下调下丘脑、脑干和小脑样本中的I型受体而非II型受体,这表明在这些脑区中,I型和II型受体集中在不同的细胞群体中,而在海马体和大脑皮层中,存在足够程度的共定位,使得醛固酮 - I型受体复合物能够通过作用下调II型受体。我们推测,这种作用至少部分是在基因组水平上介导的,即转化的醛固酮 - I型受体复合物与这些受体基因上游的DNA调控元件相互作用,抑制I型和II型受体mRNA的合成。